MSMRT - Overview: Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report

Test Catalog

Test Name

Test ID: MSMRT    
Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report

Useful For Suggests clinical disorders or settings where the test may be helpful

Risk stratification of patients with multiple myeloma, which can assist in determining treatment and management decisions


Risk stratification of patients with newly diagnosed multiple myeloma

Reflex Tests Lists tests that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial tests

Test IDReporting NameAvailable SeparatelyAlways Performed

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

See Laboratory Screening Tests for Suspected Multiple Myeloma in Special Instructions.


Based on the flow cytometric analysis and presence of greater than or equal to 0.1% monotypic plasma cells, the MPCPD / mSMART, Plasma Cell Proliferative Disorder (PCPD), FISH test will be reflexed and performed at an additional charge.

Special Instructions and Forms Library of PDFs including pertinent information and consent forms, specimen collection and preparation information, test algorithms, and other information pertinent to test

Method Name A short description of the method used to perform the test

Flow Cytometry/DNA Content/Cell Cycle Analysis

NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.


Reporting Name A shorter or abbreviated version of the Published Name for a test; an abbreviated test name

mSMART Algorithmic Testing, BM

Aliases Lists additional common names for a test, as an aid in searching

Labeling Index
Myeloma Staging
PC Proliferation
Plasma Cell Labeling Index (PCLI)
Plasma Cell Staging
+1q or CKS1B
-13 (monosomy 13)
13q- / -13 (13q deletion) or RB1
17p- (17p deletion) or TP53
IGH (14q32) rearrangement
Monoclonal Gammopathy of Unknown Significance (MGUS)
Multiple Myeloma
MYC (8q24.1) rearrangement
Plasma Cell Leukemia